Business Context and Reporting Period
This Form 8-K was filed by GlycoMimetics, Inc. (not Crescent Biopharma, Inc.) on September 28, 2017. The report details the entry into a material definitive agreement regarding a potential equity offering.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures. The primary financial metric disclosed is the potential aggregate offering price of up to $100,000,000 for shares of common stock.
Material Changes
On September 28, 2017, the Company entered into a Sales Agreement with Cowen and Company, LLC. This agreement establishes an "at-the-market" offering program allowing the Company to sell up to $100 million of common stock through Cowen as its sales agent. The issuance is contingent upon the effectiveness of a Form S-3 registration statement filed on the same date.
Guidance, Outlook, and Risks
- Commission: The Company will pay Cowen a commission of up to 3.0% of the gross sales proceeds.
- Discretion: The Company is not obligated to make any sales under the agreement and retains sole discretion over the timing and volume of sales.
- Termination: The offering will terminate upon the sale of all shares subject to the agreement or earlier termination per the agreement's terms.
- Risk: The Company makes no assurances that the registration statement will become effective or remain effective.
Investor Verification Checklist
- Verify the effectiveness status of the Form S-3 registration statement filed on September 28, 2017.
- Confirm the exact number of shares authorized for sale under the $100 million cap.
- Review the full text of the Sales Agreement (Exhibit 10.1) for specific termination clauses and indemnification details.
- Monitor future filings for actual sales activity and proceeds generated under this program.